A cost-effectiveness analysis of national smoking cessation services among chronic obstructive pulmonary disease patients in Thailand

References

• Institute for Health Metrics and Evaluation (IHME). Data from: Global Tobacco Control and Smoking Prevalence Scenarios 2017. Seattle, WA; 2020. doi: 10.6069/QAZ7-6505.
   Google Scholar
• World Health Organization. Tobacco. 2021. Available from: https://www.who.int/news-room/fact-sheets/detail/tobacco
   Google Scholar
• Böckerman P, Hyytinen A, Kaprio J. Smoking and long-term labour market outcomes. Tob Control 2015;24(4):348–353. doi: 10.1136/tobaccocontrol-2013-051303.
   PubMed Web of Science ®Google Scholar
• World Health Organization. MPOWER: a policy package to reverse the tobacco epidemic. World Health Organization; 2008.
   Google Scholar
• Ranney L, Melvin C, Lux L, McClain E, Lohr KN. Systematic review: smoking cessation intervention strategies for adults and adults in special populations. Ann Intern Med. 2006;145(11):845–856. doi: 10.7326/0003-4819-145-11-200612050-00142.
   PubMed Web of Science ®Google Scholar
• Tosanguan J, Chaiyakunapruk N. Cost-effectiveness analysis of clinical smoking cessation interventions in Thailand. Addiction. 2016;111(2):340–350. doi: 10.1111/add.13166.
   PubMed Web of Science ®Google Scholar
• Thavorn K, Chaiyakunapruk N. A cost-effectiveness analysis of a community pharmacist-based smoking cessation programme in Thailand. Tob Control. 2008;17(3):177–182. doi: 10.1136/tc.2007.022368.
   PubMed Web of Science ®Google Scholar
• Tashkin DP. Smoking cessation in chronic obstructive pulmonary disease. Semin Respir Crit Care Med. 2015;36(4):491–507. doi: 10.1055/s-0035-1555610.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Framework convention on tobacco control. Parties to the WHO FCTC. 2021. Available from: https://fctc.who.int/who-fctc/overview/parties
   Google Scholar
• Levy DT, Yuan Z, Luo Y, Mays D. Seven years of progress in tobacco control: an evaluation of the effect of nations meeting the highest level MPOWER measures between 2007 and 2014. Tob Control. 2018;27(1):50–57. doi: 10.1136/tobaccocontrol-2016-053381.
   PubMed Web of Science ®Google Scholar
• Kaur J, Rinkoo A, Gouda H, Prasad V, Pendse R. Implementation of MPOWER package in the South-East Asia Region: evidence from the WHO report on the global tobacco epidemic (2009-2021). Asian Pac J Cancer Prev. 2021;22(S2):71–80. doi: 10.31557/APJCP.2021.22.S2.71.
   PubMedGoogle Scholar
• Chaisai C, Thavorn K, Wattanasirichaigoon S, et al. The impact of Thai multidisciplinary smoking cessation program on clinical outcomes: a multicentre prospective observational study. Front Public Health. 2022;10:965020. doi: 10.3389/fpubh.2022.965020.
   PubMed Web of Science ®Google Scholar
• Burden of Disease Thailand. Thailand burden of diseases attributable to risk factor 2014. International Health Policy Program. Nonthaburi, Thailand; 2017.
   Google Scholar
• National Statistical Office. The 2021 Health Behavior of Population Survey. 2021, p. 222. Available from: http://www.nso.go.th/sites/2014en/Survey/social/health/health_behavior/2021/new_fullreport_64.pdf
   Google Scholar
• Komonpaisarn T. Economic cost of tobacco smoking and secondhand smoke exposure at home in Thailand. Tob Control 2022;31(6):714–722. doi: 10.1136/tobaccocontrol-2020-056147.
   PubMed Web of Science ®Google Scholar
• Grant A, Tan CJ, Wattanasirichaigoon S, et al. Cost-effectiveness analysis of the SMART quit clinic program in smokers with cardiovascular disease in Thailand.Tob Induc Dis. 2023;21:47–49. doi: 10.18332/tid/161024.
   PubMed Web of Science ®Google Scholar
• Kongsakon R, Sruamsiri R. A cost-utility study of smoking cessation interventions for patients with chronic obstructive pulmonary disease in Thailand. J Med Assoc Thailand. 2019;102(4):463–471.
   Google Scholar
• Bundhamcharoen K, Aungkulanon S, Makka N, Shibuya K. Economic burden from smoking-related diseases in Thailand. Tob Control. 2016;25(5):532–537. doi: 10.1136/tobaccocontrol-2015-052319.
   PubMed Web of Science ®Google Scholar
• World Bank Group. Prevalence of current tobacco use (% of adults)—Thailand, Malaysia, Vietnam, Philippines; 2023. Available from: https://data.worldbank.org/indicator/SH.PRV.SMOK?end=2020&locations=TH-MY-VN-PH&start=2020&view=bar
   Google Scholar
• Husereau D, Drummond M, Augustovski F, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS II Good Practices Task Force. Value Health. 2022;25(1):10–31. doi: 10.1016/j.jval.2021.10.008.
   PubMed Web of Science ®Google Scholar
• Singh D, Agusti A, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019. Eur Respir J. 2019;53(5):1900164. doi: 10.1183/13993003.00164-2019.
   PubMed Web of Science ®Google Scholar
• Rodthong W, Rattanachotpanit T, Limwattanano S, Limwattananon C, Lertsinudom S, Boonsawat W. Cost of illness for chronic obstructive pulmonary disease. Isan J Pharm Sci. 2015;11(1):151–158.
   Google Scholar
• World Health Organization. Life tables: Thailand. 2016. Available from: https://apps.who.int/gho/data/node.country.country-THA?lang-en
   Google Scholar
• Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE, The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med. 2005;142(4):233–239. doi: 10.7326/0003-4819-142-4-200502150-00005.
   PubMed Web of Science ®Google Scholar
• Wetter DW, Cofta-Gunn L, Fouladi RT, Cinciripini PM, Sui D, Gritz ER. Late relapse/sustained abstinence among former smokers: a longitudinal study. Prev Med. 2004;39(6):1156–1163. doi: 10.1016/j.ypmed.2004.04.028.
   PubMed Web of Science ®Google Scholar
• Krall EA, Garvey AJ, Garcia RI. Smoking relapse after 2 years of abstinence: findings from the VA Normative Aging Study. Nicotine Tob Res. 2002;4(1):95–100. doi: 10.1080/14622200110098428.
   PubMedGoogle Scholar
• Hoogendoorn M, Rutten-van Molken MP, Hoogenveen RT, et al. A dynamic population model of disease progression in COPD. Eur Respir J. 2005;26(2):223–233. doi: 10.1183/09031936.05.00122004.
   PubMed Web of Science ®Google Scholar
• Parimon T, Chien JW, Bryson CL, McDonell MB, Udris EM, Au DH. Inhaled corticosteroids and risk of lung cancer among patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175(7):712–719. doi: 10.1164/rccm.200608-1125OC.
   PubMed Web of Science ®Google Scholar
• Phunmanee A, Wirasorn K, Thavornpitak Y, Sookprasert A, Chindaprasirt J. Lung cancer in hospitalized patients of Thailand. J Med Assoc Thai. 2012;95(Suppl 7):S201–S205.
   PubMedGoogle Scholar
• Ståhl E, Lindberg A, Jansson S-A, et al. Health-related quality of life is related to COPD disease severity. Health Qual Life Outcomes. 2005;3(1):56. doi: 10.1186/1477-7525-3-56.
   PubMedGoogle Scholar
• Howard P, Knight C, Boler A, Baker C. Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO simulation model: application to a population of US adult smokers. Pharmacoeconomics. 2008;26(6):497–511. doi: 10.2165/00019053-200826060-00004.
   PubMed Web of Science ®Google Scholar
• Paterson C, Langan CE, McKaig GA, et al. Assessing patient outcomes in acute exacerbations of chronic bronchitis: the measure your medical outcome profile (MYMOP), medical outcomes study 6-item general health survey (MOS-6A) and EuroQol (EQ-5D).Qual Life Res. 2000;9(5):521–527. doi: 10.1023/a:1008930521566.
   PubMed Web of Science ®Google Scholar
• Spencer M, Briggs AH, Grossman RF, Rance L. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics. 2005;23(6):619–637. doi: 10.2165/00019053-200523060-00008.
   PubMed Web of Science ®Google Scholar
• Chaikledkaew U, Kittrongsiri K. Guidelines for health technology assessment in Thailand (second edition)-the development process. J Med Assoc Thailand. 2014;97(SUPPL. 5):S4–S9.
   PubMedGoogle Scholar
• Guideline Development Working Group. Thailand’s Health Technology Assessment (HTA) guideline. 2nd ed. Nonthaburi (Thailand): Watcharin P.P. printing; 2013.
   Google Scholar
• Riewpaiboon A. Standard cost lists for health economic evaluation in Thailand. J Med Assoc Thailand. 2014;97(SUPPL. 5):S127–S134.
   PubMedGoogle Scholar
• Bureau of Trade and Economic Indices. Consumer Price Index (CPI) of Thailand. Bureau of Trade and Economic Indices, Ministry of Commerce. 2017. Available from: http://www.price.moc.go.th/price/cpi/index_new_all.asp
   Google Scholar
• Bank of Thailand. Historical foreign exchange rates. Bank of Thailand. 2017. Available from: https://www.bot.or.th/App/BTWS_STAT/statistics/ReportPage.aspx?reportID=123&language=eng
   Google Scholar
• Hoogendoorn M, Feenstra TL, Hoogenveen RT, Rutten-van Mölken MPMH. Long-term effectiveness and cost-effectiveness of smoking cessation interventions in patients with COPD. Thorax 2010;65(8):711–718. doi: 10.1136/THX.2009.131631.
   PubMed Web of Science ®Google Scholar
• Chandra K, Blackhouse G, McCurdy BR, et al. Cost-effectiveness of interventions for chronic obstructive pulmonary disease (COPD) using an Ontario policy model. Ont Health Technol Assess Ser. 2012;12:1–61. http://www.hqontario.ca/en/mas/mas_ohtas_mn.html. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3384363/pdf/ohtas-12-61.pdf
   Google Scholar
• Faulkner MA, Lenz TL, Stading JA. Cost-effectiveness of smoking cessation and the implications for COPD. Int J COPD. 2006;1(3):279–287. doi: 10.2147/copd.2006.1.3.279.
   Google Scholar
• Menn P, Leidl R, Holle R. A lifetime Markov model for the economic evaluation of chronic obstructive pulmonary disease. Pharmacoeconomics 2012;30(9):825–840. doi: 10.2165/11591340-000000000-00000.
   PubMed Web of Science ®Google Scholar
• Atsou K, Chouaid C, Hejblum G. Simulation-based estimates of effectiveness and cost-effectiveness of smoking cessation in patients with chronic obstructive pulmonary disease. PLoS One. 2011;6(9):e24870. doi: 10.1371/journal.pone.0024870.
   PubMed Web of Science ®Google Scholar
• Ministry of Public H. Public Health Statistics A.D.2017. 2018. Available from: https://bps.moph.go.th/new_bps/sites/default/files/stratistics60.pdf
   Google Scholar
• Chen B, Silvestri GA, Dahne J, Lee K, Carpenter MJ. The cost-effectiveness of nicotine replacement therapy sampling in primary care: a Markov cohort simulation model. J Gen Intern Med. 2022;37(14):3681–3691. doi: 10.1007/s11606-021-07335-x.
   Web of Science ®Google Scholar
• Kirsch F. A systematic review of quality and cost-effectiveness derived from Markov models evaluating smoking cessation interventions in patients with chronic obstructive pulmonary disease. Expert Rev Pharmacoecon Outcomes Res. 2015;15(2):301–316. doi: 10.1586/14737167.2015.1001976.
   PubMed Web of Science ®Google Scholar
• Hoogendoorn M, Feenstra TL, Asukai Y, et al. Cost-effectiveness models for chronic obstructive pulmonary disease: cross-model comparison of hypothetical treatment scenarios. Value Health. 2014;17(5):525–536. doi: 10.1016/j.jval.2014.03.1721.
   PubMed Web of Science ®Google Scholar
• Kendzor DE, Businelle MS, Costello TJ, et al. Financial strain and smoking cessation among racially/ethnically diverse smokers. Am J Public Health. 2010;100(4):702–706. doi: 10.2105/AJPH.2009.172676.
   PubMed Web of Science ®Google Scholar
• Reitzel LR, Langdon KJ, Nguyen NT, Zvolensky MJ. Financial strain and smoking cessation among men and women within a self-guided quit attempt. Addict Behav. 2015;47:66–69. doi: 10.1016/j.addbeh.2015.03.026.
   PubMed Web of Science ®Google Scholar
• Siahpush M, Carlin JB. Financial stress, smoking cessation and relapse: results from a prospective study of an Australian national sample. Addiction. 2006;101(1):121–127. doi: 10.1111/j.1360-0443.2005.01292.x.
   PubMed Web of Science ®Google Scholar